Moderna Flu Vaccine Vaccine shows positive test results by paving the way to a combined shot

Modern Monday said his experiment based on mRNA vaccine vs flu Produced a stronger immune response than available currently shot in the late stage test, clearing the way forward for the product and a separate combined flu company and Covid Jab.

Moderna in May voluntarily withdrawn the application Seeking the approval of his combined shot focused on COVID-19 and the flu, saying he plans to re-send it with the data efficiency from the third stage at his autonomous flu vaccine. Such a decision came after the discussion of the nutrition and medicine management, which fights a large overhaul for health care and health secretary Robert F. Kennedy, the younger, known skeptics of the vaccine.

With new data, the company plans to re -send the application to the combined vaccine and submit its autonomous flu at the end of this year, Stephen Hodg, head of research and development said in an interview.

If the regulators approve of the flu vaccine, the company may promote a combined shot, HOD said. He added that Moderna is waiting for permission for both shots next year before reviews.

On Monday, Moderna shares increased by almost 3%.

Hodge said the combination of Jab simplifies the vaccination that will “help the healthcare system”, reducing the load of doctors and nurses, reducing costs and improving the absorption among patients.

The company still seems to be the main plot in the race against Pfizer and Novavax to bring a combined shot to the market. While Moderna has no specific income forecasts for its individual products, HOGE said that COVID virus, flu and respiratory syncytial is multibillion-dollar markets.

“We obviously hope that our products will allow us to earn our share in them,” he said.

The third test in the third stage followed more than 40,000 adults aged 50 and above, which were randomly designed to obtain a single dose of Moderna’s shot, called mRNK-1010, or a standard competitor vaccine. The Moderna shot was 26.6% more efficient than another vaccine in the overall study population.

MRNK-1010 Jab has also demonstrated high efficiency for each of the main flu strains in the shot, including A/H1N1, A/H3N2 and B/Victoria. Moderna said the benefit of the vaccine meets different ages, people with different risk factors and pre -flu vaccination status.

In adults at the age of 65, the shot was 27.4% more effective than the standard flu vaccine.

The results of the efficiency are “a significant milestone in our efforts to reduce the weight of the influenza in elderly adults,” said Moderna CEO Stefan Bancel in the release. “The burden of this flu last season emphasizes the need for more effective vaccines.”

Modern cited data From the centers for control and prevention of diseases, which show that seasonal hospitalization associated with influenza and outpatient visits reached a 15-year high during the 2024 virus season. More than 600,000 Americans were hospitalized due to influenza disease last year, CDC reports.

MRNK-1010 safety data corresponded to the previous result of another study of the third phase in the picture.

Moderna’s shares have fallen by more than 30% per year, which is received on Monday, largely caused by a number of Trump administration to change the vaccine policy and undermine vaccinations. Administration in May disassembled The contract provided by Moderna for developing the late stage of the bird vaccine for humans.

Asked about the uncertain normative environment in the US, Hodge said Moderna cooperates closely with the FDA to understand what his requirements are and how to meet them.

“I believe that, as it is connected with the flu, I think we have a pretty clear way,” he said.